Brief: Rani Therapeutics Announces Preclinical Data Demonstrating Bioequivalence Of RT-114, A GLP-1/GLP-2 Dual Agonist (PG-102) Delivered Orally Via The RaniPill Capsule, To Subcutaneously Administered PG-102
26/03/2025 20:10
March 26 (Reuters) - Rani Therapeutics Holdings Inc RANI.O: RANI THERAPEUTICS ANNOUNCES PRECLINICAL DATA DEMONSTRATING BIOEQUIVALENCE OF RT-114, A GLP-1/GLP-2 DUAL AGONIST (PG-102) DELIVERED ORALLY VIA THE RANIPILL® CAPSULE, TO SUBCUTANEOUSLY ADMINISTERED PG-102 RANI THERAPEUTICS HOLDINGS: PHASE 1 CLINICAL STUDY FOR RT-114 FOR TREATMENT OF OBESITY EXPECTED TO INITIATE IN MID- 2025 Source text: ID:nGNX8h90rs Further company coverage: RANI.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Rani Therapeutics Holdings
See all newsRani Therapeutics Q2 net loss narrows as revenue rises helped by Chugai agreement
Brief: Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
Brief: Pegbio Co Enters MoU With Rani Therapeutics
Brief: Rani Therapeutics Announces R&D Collaboration With PegBio
Rani Therapeutics Q1 contract revenue rises on Chugai collaboration; announces CFO transition